Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American ...

ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using ...

Global CAR T-cell Therapy Market OverviewThe global CAR T-cell therapy market is poised for exceptional growth, with an ...

Nektar Therapeutics stock is upgraded from 'Buy' to 'Strong Buy' following robust phase 2b data for REZPEG in atopic ...

Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s ...

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen ...

Lilly will pay $3.25 billion upfront with possible additional payments linked to the achievement of clinical, regulatory, and commercial milestones.

Janos L. Tanyi, MD, PhD, of Penn Medicine, shared an early report of a new type of CAR T cell therapy, called KIR-CAR, in a Clinical Trial Plenary session at the AACR Annual Meeting 2026.

Adds dedicated business development leadership to support Tempest’s strategic prioritiesWill lead China outreach and ...

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to announce that the ...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine ...

A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...